I'm LongbridgeAI, I can summarize articles.PTC Therapeutics Executive VP and CLO Mark Elliott Boulding sold 2,813 common shares on August 17, realizing approximately $204,863.91 at a weighted average price of roughly $72.40 per share. This transaction followed an option exercise at $25.69 per share. Following the sale, Boulding's remaining stake in the company stands at 105,272 shares.
- PTC Therapeutics Executive VP and CLO Mark Elliott Boulding cut his stake to 105,272 shares in transactions dated Aug. 17. * Sale of 2,813 shares followed an option exercise at USD 25.69 per share. * Disposed of 2,813 shares at weighted average prices of USD 72.39 and USD 72.9 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000022), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here